| Literature DB >> 30081603 |
Hiep X Nguyen1, Ajay K Banga2.
Abstract
In this study, we used sonophoresis and iontophoresis to enhance the in vitro delivery of methotrexate through human cadaver skin. Iontophoresis was applied for 60 min at a 0.4 mA/sq·cm current density, while low-frequency sonophoresis was applied at a 20 kHz frequency (2 min application, and 6.9 W/sq·cm intensity). The treated skin was characterized by dye binding, transepidermal water loss, skin electrical resistance, and skin temperature measurement. Both sonophoresis and iontophoresis resulted in a significant reduction in skin electrical resistance as well as a marked increase in transepidermal water loss value (p < 0.05). Furthermore, the ultrasonic waves resulted in a significant increase in skin temperature (p < 0.05). In permeation studies, the use of iontophoresis led to a significantly higher drug permeability than the untreated group (n = 4, p < 0.05). The skin became markedly more permeable to methotrexate after the treatment by sonophoresis than by iontophoresis (p < 0.01). A synergistic effect for the combined application of sonophoresis and iontophoresis was also observed. Drug distribution in the skin layers revealed a significantly higher level of methotrexate in the sonicated skin than that in iontophoresis and untreated groups. Iontophoresis and low-frequency sonophoresis were found to enhance the transdermal and intradermal delivery of methotrexate in vitro.Entities:
Keywords: characterization; iontophoresis; methotrexate; sonophoresis; transdermal delivery
Year: 2018 PMID: 30081603 PMCID: PMC6161078 DOI: 10.3390/pharmaceutics10030117
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Experimental setup of (A) low-frequency sonophoresis (LFS), (B) anodal iontophoresis (anodal ITP), and (C) cathodal iontophoresis (cathodal ITP).
Experimental setup of in vitro permeation studies (n = 4).
| Compartment | Passive a | Anodal ITP b | Cathodal ITP c | LFS d | Anodal ITP b + LFS d | Cathodal ITP c + LFS d |
|---|---|---|---|---|---|---|
| Donor | 500 µL MTX 2.0 mg/mL in 10 mM PBS | 500 µL MTX 2.0 mg/mL in 10 mM PBS (75 mM NaCl f) | 500 µL MTX 2.0 mg/mL in 10 mM PBS | 500 µL MTX 2.0 mg/mL in 10 mM PBS | 500 µL MTX 2.0 mg/mL in 10 mM PBS (75 mM NaCl f) | 500 µL MTX 2.0 mg/mL in 10 mM PBS |
| Receptor | 5 mL PBS (10 mM) | 5 mL PBS (10 mM) | 5 mL PBS (10 mM, 75 mM NaCl f) | 5 mL PBS (10 mM) | 5 mL PBS (10 mM) | 5 mL PBS (10 mM, 75 mM NaCl f) |
| Skin pretreatment | NA e | NA e | NA e | Two-min LFS, 100% duty cycle | Two-min LFS, 100% duty cycle | Two-min LFS, 100% duty cycle |
a No delivery technology (ITP, sonophoresis), only passive diffusion. b Anodal ITP, described in Figure 1B. c Cathodal ITP, described in Figure 1C. d LFS operating at 20 kHz frequency, two-minute application, 100% duty cycle, 0.3 cm distance between the sonicator probe and the skin surface, 1% (w/v) sodium lauryl sulfate as the coupling medium, and 30% amplitude, described in Figure 1A. e No pretreatment on skin tissues. f NaCl (75 mM) was added to drive the electrochemistry [26].
Figure 2Microscopic images of (A) untreated dermatomed human skin and skin treated by (B) anodal ITP, (C) cathodal ITP, and (D) LFS.
Figure 3(A) Electrical resistance, (B) transepidermal water loss, and (C) increase in the temperature of dermatomed human cadaver skin (* indicated statistical difference from the LFS, mean ± SD, n = 4, p < 0.05).
Transdermal delivery, lag time, flux, permeability coefficient, and steady-state plasma concentration of in vitro permeation of MTX though dermatomed human cadaver skin (mean ± SD, n = 4).
| Group | Lag Time b (h) | ||||
|---|---|---|---|---|---|
| Passive | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Anodal ITP | 4.74 ± 0.62 | 3.57 ± 1.07 | 0.05 ± 0.03 | 0.26 ± 0.14 | 0.28 ± 0.15 |
| Cathodal ITP | 0.54 ± 0.07 | 0.20 ± 0.05 | 0.01 ± 0.00 | 0.07 ± 0.02 | 0.08 ± 0.02 |
| LFS | 161.92 ± 30.06 | −5.09 ± 1.03 | 6.81 ± 1.31 | 34.04 ± 6.55 | 36.92 ± 7.11 |
| Anodal ITP + LFS | 333.10 ± 37.01 | 11.83 ± 10.77 | 13.42 ± 1.95 | 67.08 ± 9.73 | 72.77 ± 10.55 |
| Cathodal ITP + LFS | 178.30 ± 23.79 | −15.93 ± 16.74 | 8.03 ± 1.17 | 40.14 ± 5.85 | 43.54 ± 6.35 |
a Cumulative amount of MTX (Q24) permeated through a unit of diffusion area in 24 h. b Lag time—calculated as the x-intercept of the linear portion of the permeation curve (R > 0.90). c Steady-state flux (J)—calculated from the linear slope of the permeation curve. d Permeability coefficient (Kp)—calculated using an equation: Kp = J/CA, where K is the permeability coefficient (cm/h), J is the steady-state flux (µg/h), C is the MTX concentration in the donor (µg/mL), and A is the permeation area (0.64 sq.cm). e Steady-state plasma concentration (C)—calculated using an equation: Css = (A × Jss)/Cl, where Css is the steady-state plasma concentration (µg/mL), A is the permeation area of skin (0.64 sq·cm), Jss is the steady-state flux (µg/sq·cm/h), and Cl is the clearance of MTX from the body.
Figure 4(A) Average cumulative amount and (B) flux of methotrexate (MTX) delivered through untreated, ITP, and sonophoresis-treated dermatomed human cadaver skin (* indicated statistical difference from the passive group, mean ± SD, n = 4, p < 0.05).
Figure 5Levels of MTX in dermatomed human cadaver skin (* indicated statistical difference from the passive, anodal, and cathodal ITP, mean ± SD, n = 4, p < 0.05).